Part 7/12:
John R. Sullivan, Head of Data 42, emphasizes that combining vast datasets, scientific expertise, and intelligent algorithms can completely overhaul the traditionally slow and uncertain drug discovery pipeline. Such innovations mark a new era where science and AI together can turn years of trial, error, and expense into rapid, reliable insights.